Diminished Expression of Corticotropin-Releasing Hormone Receptor 2 in Human Colon Cancer Promotes Tumor Growth and Epithelial-to-Mesenchymal Transition via Persistent Interleukin-6/Stat3 Signaling

Cellular and Molecular Gastroenterology and Hepatology

Volumn 1, Issue 6, 2015, Pages 610-630

  Rodriguez, Jorge A ^a   Huerta Yepez, Sara ^b   Law, Ivy Ka Man ^a   Baay Guzman, Guillermina J ^b   Tirado Rodriguez, Belen ^b   Hoffman, Jill M ^a   Iliopoulos, Dimitrios ^a   Hommes, Daniel W ^a,c   Verspaget, Hein W ^c   Chang, Lin ^a   Pothoulakis, Charalabos ^a   Baritaki, Stavroula ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CRETE   (Greece)

Author keywords

Colorectal cancer; Inflammation; Metastasis; Neuropeptides

Indexed keywords

CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; STAT3 PROTEIN; UROCORTIN II; UVOMORULIN; VIMENTIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; COLONY FORMATION; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR XENOGRAFT;

EID: 84944459450     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2015.08.001     Document Type: Article

References (51)

1. Terzic J., Grivennikov S., Karin E., et al. Inflammation and colon cancer. Gastroenterology 2010, 138:2101-2114.e5.
2. Gay J., Kokkotou E., O'Brien M., et al. Corticotropin-releasing hormone deficiency is associated with reduced local inflammation in a mouse model of experimental colitis. Endocrinology 2008, 149:3403-3409.
3. Paschos K.A., Kolios G., Chatzaki E. The corticotropin-releasing factor system in inflammatory bowel disease: prospects for new therapeutic approaches. Drug Discov Today 2009, 14:713-720.
4. Moss A.C., Anton P., Savidge T., et al. Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha. Gut 2007, 56:1210-1217.
5. Chang J., Hoy J.J., Idumalla P.S., et al. Urocortin 2 expression in the rat gastrointestinal tract under basal conditions and in chemical colitis. Peptides 2007, 28:1453-1460.
6. Reubi J.C., Waser B., Vale W., et al. Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab 2003, 88:3312-3320.
7. Suda T., Tomori N., Yajima F., et al. Characterization of immunoreactive corticotropin and corticotropin-releasing factor in human adrenal and ovarian tumours. Acta Endocrinol (Copenh) 1986, 111:546-552.
8. Miceli F., Ranelletti F.O., Martinelli E., et al. Expression and subcellular localization of CRH and its receptors in human endometrial cancer. Mol Cell Endocrinol 2009, 305:6-11.
9. Ciocca D.R., Puy L.A., Fasoli L.C., et al. Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients. Breast Cancer Res Treat 1990, 15:175-184.
10. Minas V., Rolaki A., Kalantaridou S.N., et al. Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br J Cancer 2007, 97:637-645.
11. Jo Y.H., Choi Y.J., Kim H.O., et al. Corticotropin-releasing hormone enhances the invasiveness and migration of Ishikawa cells, possibly by increasing matrix metalloproteinase-2 and matrix metalloproteinase-9. J Int Med Res 2011, 39:2067-2075.
12. Graziani G., Tentori L., Portarena I., et al. CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 2002, 143:807-813.
13. Graziani G., Tentori L., Muzi A., et al. Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol 2007, 264:44-49.
14. Chatzaki E., Lambropoulou M., Constantinidis T.C., et al. Corticotropin-releasing factor (CRF) receptor type 2 in the human stomach: protective biological role by inhibition of apoptosis. J Cell Physiol 2006, 209:905-911.
15. Wang J., Xu Y., Xu Y., et al. Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest 2008, 26:359-368.
16. Tezval H., Jurk S., Atschekzei F., et al. The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways. Prostate 2009, 69:443-448.
17. Ducarouge B., Pelissier-Rota M., Laine M., et al. CRF2 signaling is a novel regulator of cellular adhesion and migration in colorectal cancer cells. PLoS One 2013, 8:e79335.
18. Hernandez-Cueto A., Hernandez-Cueto D., Antonio-Andres G., et al. Death receptor 5 expression is inversely correlated with prostate cancer progression. Mol Med Rep 2014, 10:2279-2286.
19. Corvinus F.M., Orth C., Moriggl R., et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005, 7:545-555.
20. Baritaki S., Chapman A., Yeung K., et al. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene 2009, 28:3573-3585.
21. Baritaki S., Huerta-Yepez S., Sahakyan A., et al. Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP. Cell Cycle 2010, 9:4931-4940.
22. Rokavec M., Oner M.G., Li H., et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest 2014, 124:1853-1867.
23. Tanaka T. Animal models of carcinogenesis in inflamed colorectum: potential use in chemoprevention study. Curr Drug Targets 2012, 13:1689-1697.
24. Klampfer L. The role of signal transducers and activators of transcription in colon cancer. Front Biosci 2008, 13:2888-2899.
25. Lopez-Novoa J.M., Nieto M.A. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 2009, 1:303-314.
26. Mueller M.M., Fusenig N.E. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4:839-849.
27. Liu Y., Fang X., Yuan J., et al. The role of corticotropin-releasing hormone receptor 1 in the development of colitis-associated cancer in mouse model. Endocr Relat Cancer 2014, 21:639-651.
28. Dermitzaki E., Tsatsanis C., Minas V., et al. Corticotropin-releasing factor (CRF) and the urocortins differentially regulate catecholamine secretion in human and rat adrenals, in a CRF receptor type-specific manner. Endocrinology 2007, 148:1524-1538.
29. Im E., Rhee S.H., Park Y.S., et al. Corticotropin-releasing hormone family of peptides regulates intestinal angiogenesis. Gastroenterology 2010, 138:2457-2467. e1-5.
30. Kokkotou E., Torres D., Moss A.C., et al. Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J Immunol 2006, 177:3355-3361.
31. Wlk M., Wang C.C., Venihaki M., et al. Corticotropin-releasing hormone antagonists possess anti-inflammatory effects in the mouse ileum. Gastroenterology 2002, 123:505-515.
32. Tsatsanis C., Androulidaki A., Dermitzaki E., et al. Urocortin 1 and urocortin 2 induce macrophage apoptosis via CRFR2. FEBS Lett 2005, 579:4259-4264.
33. Kageyama K., Hanada K., Nigawara T., et al. Urocortin induces interleukin-6 gene expression via cyclooxygenase-2 activity in aortic smooth muscle cells. Endocrinology 2006, 147:4454-4462.
34. Jarnicki A., Putoczki T., Ernst M. Stat3: linking inflammation to epithelial cancer-more than a "gut" feeling?. Cell Div 2010, 5:14.
35. Spano J.P., Milano G., Rixe C., et al. JAK/STAT signalling pathway in colorectal cancer: a new biological target with therapeutic implications. Eur J Cancer 2006, 42:2668-2670.
36. Waldner M.J., Foersch S., Neurath M.F. Interleukin-6-a key regulator of colorectal cancer development. Int J Biol Sci 2012, 8:1248-1253.
37. Bromberg J.F., Wrzeszczynska M.H., Devgan G., et al. Stat3 as an oncogene. Cell 1999, 98:295-303.
38. Masuda M., Suzui M., Yasumatu R., et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002, 62:3351-3355.
39. Bowman T., Broome M.A., Sinibaldi D., et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 2001, 98:7319-7324.
40. Bollrath J., Phesse T.J., von Burstin V.A., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
41. Kanda N., Seno H., Konda Y., et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004, 23:4921-4929.
42. Chen C.L., Cen L., Kohout J., et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer 2008, 7:78.
43. O'Connor D.S., Grossman D., Plescia J., et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000, 97:13103-13107.
44. Niu G., Wright K.L., Ma Y., et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 2005, 25:7432-7440.
45. Joyce T., Cantarella D., Isella C., et al. A molecular signature for Epithelial to Mesenchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysis. Clin Exp Metastasis 2009, 26:569-587.
46. Xiong H., Hong J., Du W., et al. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J Biol Chem 2012, 287:5819-5832.
47. Jin L., Li C., Li R., et al. Corticotropin-releasing hormone receptors mediate apoptosis via cytosolic calcium-dependent phospholipase A(2) and migration in prostate cancer cell RM-1. J Mol Endocrinol 2014, 52:255-267.
48. Zhu C., Sun Z., Li C., et al. Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2. Cell Signal 2014, 26:1125-1134.
49. Colomiere M., Ward A.C., Riley C., et al. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 2009, 100:134-144.
50. Yadav A., Kumar B., Datta J., et al. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res 2011, 9:1658-1667.
51. Wei D., Le X., Zheng L., et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003, 22:319-329.